CTOs on the Move

Heritage Pharmaceuticals

www.heritagepharma.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

ANI Pharmaceuticals

ANI Pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. Our two pharmaceutical manufacturing facilities located in Baudette, Minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. Our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize Cortrophin gel and Cortrophin-Zinc.

The START Center for Cancer Care

The START Center offers some of the most sophisticated treatment options available in South Texas along with the world’s largest and most active Phase I clinical trials program. The START Center also offers the Inspiritas Spa and Wellness Center whic...

Trinity Biotech

Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits.

Summit Spine & Joint Centers

For compassionate and convenient care, Summit Spine & Joint Centers is the pain clinic you can trust. We provide treatment for a wide range of conditions. Call us today at (770) 962-3642.

Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.